Antituberculous Treatment Itself Might Prevent Visual Impairment in Presumed Tuberculosis-Related Uveitis

Ocul Immunol Inflamm. 2020;28(1):103-110. doi: 10.1080/09273948.2018.1541326. Epub 2018 Nov 5.

Abstract

Purpose: To study the risk factors for visual loss in presumed tuberculosis-related uveitis (TRU).Methods: Retrospective observational cohort study of patients with TRU, either treated or not for tuberculosis, from January 2005 to January 2017. Clinical and demographic variables were recorded. Main outcome measure was a loss of visual acuity (VA) of ≥2 Snellen lines. A Generalized Estimation Equation was used to control between-eyes bias. A backward stepwise logistic regression multivariate analysis was conducted to elucidate independent risk factors.Results: One hundred and thirty-eight eyes from 82 patients were included. There were 45 males, median age at onset of uveitis was 40 years (Interquartile range, IQR 24). The median follow-up was 36 months (IQR 49.75) and 51 patients completed antituberculous treatment (ATT) for a mean of 9.37 months. In the multivariate model, ATT was the only independent protective factor for loss of VA (OR 0.13, 95% CI 0.04-0.37, p < 0.001).Conclusion: ATT itself may prevent visual loss in TRU.

Keywords: Clinical features; complications; outcome; risk factors; treatment; tuberculosis; uveitis; visual acuity.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Aged
  • Antitubercular Agents / therapeutic use*
  • Cohort Studies
  • Female
  • Follow-Up Studies
  • Humans
  • Interferon-gamma Release Tests
  • Male
  • Middle Aged
  • Retrospective Studies
  • Tuberculin Test
  • Tuberculosis, Ocular / diagnosis
  • Tuberculosis, Ocular / drug therapy*
  • Uveitis / diagnosis
  • Uveitis / drug therapy*
  • Vision Disorders / prevention & control*
  • Visual Acuity / physiology

Substances

  • Antitubercular Agents